Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018Jonathan M. Loree, Kanwal Raghav, Seerat Anand et al.|JAMA Oncology|2019Cited by 568
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaperArvind Dasari, Scott Kopetz, Van K. Morris et al.|Nature Reviews Clinical Oncology|2020Cited by 365
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 studyArvind Dasari, Cathy Eng, François Ghiringhelli et al.|The Lancet|2023Cited by 319
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular SubtypesJonathan M. Loree, Scott Kopetz, Allan Andresson Lima Pereira et al.|Clinical Cancer Research|2017Cited by 318
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challengeChristine M. Parseghian, Scott Kopetz, Jonathan M. Loree et al.|Annals of Oncology|2018Cited by 239